片仔癀胶囊治疗EGFRI相关性皮疹的临床疗效及其机制

被引:0
作者
王富强
机构
[1] 福建中医药大学
关键词
片仔癀胶囊; 表皮生长因子受体; 抑制剂; 皮疹; 炎症因子;
D O I
暂无
年度学位
2013
学位类型
硕士
摘要
目的:1)观察中成药片仔癀胶囊治疗EGFRI相关性皮疹的临床疗效;2)检测分析中成药片仔癀胶囊治疗前后,外周血炎症因子(TNF-α、IL-1β、IL-6)水平变化,观察其可能的疗效作用机制。 方法:收集2011年12月至2012年12月符合入组条件的EGFRI相关性皮疹患者60例,随机分为2组:试验组30例,采用中成药片仔癀胶囊治疗;对照组30例,未给予任何皮肤用药及抗炎药物。观察中成药片仔癀胶囊治疗4周前后患者功能状态评分(KPS)、皮疹情况,同时用生物素双抗体夹心酶联免疫吸附法(ELISA)检测血清中TNF-α、IL-1β、IL-6水平。所有数据应用SPSS16.0软件进行统计分析。 结果: 1)临床疗效:①皮疹改善情况:试验组:痊愈3例(10.0%),有效23例(76.7%),无效4例(13.3%),总有效率为86.67%;对照组:痊愈0例(0%),有效3例(10.0%),无效27例(90.0%),总有效率为10.0%;两组相比有显著性差异(P<0.01)。②生活质量改善情况:治疗4周后,试验组KPS评分较治疗前明显上升(P<0.01),对照组改善不明显(P>0.05),两组间有显著差异(P<0.05)。 2)外周血炎症细胞因子(TNF-α、IL-1β、IL-6)水平:试验组血清TNF-α水平较治疗前明显下降(P<0.01),与对照组相比有显著差异(P<0.01);试验组血清IL-1β水平较治疗前明显下降(P<0.01),与对照组相比有显著差异(P<0.01);试验组血清IL-6水平较治疗前明显下降(P<0.01),与对照组相比有显著差异(P<0.01)。 3)将试验组治疗前后3项指标(TNF-α、IL-1β、IL-6)差值与皮疹、生活质量改善情况进行相关性分析,提示有相关性(P<0.05)。结论:片仔癀胶囊治疗EGFRI目关性皮疹,有助于提高KPS评分,改善皮疹临床症状;片仔癀胶囊治疗EGFRI目关性皮疹,能显著地下调TNF-α、IL-1、IL-6水平,抑制炎症的发展,从而发挥临床疗效。
引用
收藏
页数:38
共 21 条
[1]
Relationship between skin rash and outcome in non-small-cell lung cancer patients treated with anti-EGFR tyrosine kinase inhibitors: A literature-based meta-analysis of 24 trials [J].
Petrelli, Fausto ;
Borgonovo, Karen ;
Cabiddu, Mary ;
Lonati, Veronica ;
Barni, Sandro .
LUNG CANCER, 2012, 78 (01) :8-15
[2]
Erlotinib-Induced Skin Rash. Pathogenesis, Clinical Significance and Management in Pancreatic Cancer Patients [J].
Saif, Muhammad Wasif ;
Merikas, Irene ;
Tsimboukis, Sotirios ;
Syrigos, Kostas .
JOURNAL OF THE PANCREAS, 2008, 9 (03) :267-274
[3]
Severe lung and skin toxicity during treatment with gemcitabine and erlotinib for metastatic pancreatic cancer [J].
Boeck, Stefan ;
Hausmann, Andreas ;
Reibke, Roland ;
Schulz, Christoph ;
Heinemann, Volker .
ANTI-CANCER DRUGS, 2007, 18 (09) :1109-1111
[4]
Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non-small-cell lung cancer [J].
Heymach, John V. ;
Johnson, Bruce E. ;
Prager, Diane ;
Csada, Edit ;
Roubec, Jaromir ;
Pesek, Milos ;
Spasova, Irena ;
Belani, Chandra P. ;
Bodrogi, Istvan ;
Gadgeel, Shirish ;
Kennedy, Sarah J. ;
Hou, Jeannie ;
Herbst, Roy S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (27) :4270-4277
[5]
Nail toxicity associated with epidermal growth factor receptor inhibitor therapy [J].
Fox, Lindy P. .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2007, 56 (03) :460-465
[6]
Predictive and pharmacodynamic biomarker studies in tumor and skin tissue samples of patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with erlotinib [J].
Agulnik, Mark ;
da Cunha Santos, Gilda ;
Hedley, David ;
Nicklee, Trudey ;
dos Reis, Patricia Pintor ;
Ho, James ;
Pond, Gregory R. ;
Chen, Heidi ;
Chen, Shuo ;
Shyr, Yu ;
Winquist, Eric ;
Soulieres, Denis ;
Chen, Eric X. ;
Squire, Jeremy A. ;
Marrano, Paula ;
Kamel-Reid, Suzanne ;
Dancey, Janet ;
Siu, Lillian L. ;
Tsao, Ming S. .
JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) :2184-2190
[7]
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer [J].
Pérez-Soler, R ;
Chachoua, A ;
Hammond, LA ;
Rowinsky, EK ;
Huberman, M ;
Karp, D ;
Rigas, J ;
Clark, GM ;
Santabàrbara, P ;
Bonomi, P .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (16) :3238-3247
[8]
Antitumor activity of erlotinib (OSI-774, Tarceva) alone or in combination in human non-small cell lung cancer tumor xenograft models [J].
Higgins, B ;
Kolinsky, K ;
Smith, M ;
Beck, G ;
Rashed, M ;
Adames, V ;
Linn, M ;
Wheeldon, E ;
Gand, L ;
Birnboeck, H ;
Hoffmann, G .
ANTI-CANCER DRUGS, 2004, 15 (05) :503-512
[9]
The EGF receptor - an essential regulator of multiple epidermal functions [J].
Jost, M ;
Kari, C ;
Rodeck, U .
EUROPEAN JOURNAL OF DERMATOLOGY, 2000, 10 (07) :505-510
[10]
CIRCULATING HUMAN PERIPHERAL-BLOOD GRANULOCYTES SYNTHESIZE AND SECRETE TUMOR NECROSIS FACTOR-ALPHA [J].
DUBRAVEC, DB ;
SPRIGGS, DR ;
MANNICK, JA ;
RODRICK, ML .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (17) :6758-6761